{
  "question_stem": {
    "en": "Pharmacology researchers develop a novel immunotherapy to treat malignancies. In this therapy, T lymphocytes are harvested from patients with a malignancy and genetically modified to express a chimeric antigen receptor composed of an extracellular antigen recognition domain linked with an intracellular T-cell signaling domain. These modified T cells are expanded ex vivo and then infused back into the patient, where they destroy the cancer cells. In one of the experiments, they modify the chimeric antigen receptor to recognize CD19. Use of this treatment is most likely to have which of the following potential complications?",
    "zh": "药理学研究人员开发了一种新型免疫疗法来治疗恶性肿瘤。在这种疗法中，从患有恶性肿瘤的患者身上提取T淋巴细胞，并进行基因修饰以表达嵌合抗原受体，该受体由细胞外抗原识别结构域与细胞内T细胞信号传导结构域相连组成。这些修饰后的T细胞在体外扩增，然后回输到患者体内，在那里它们会破坏癌细胞。在其中一项实验中，他们修饰了嵌合抗原受体以识别CD19。使用这种治疗方法最有可能出现以下哪种潜在并发症？"
  },
  "question": {
    "en": "Use of this treatment is most likely to have which of the following potential complications?",
    "zh": "使用这种治疗方法最有可能出现以下哪种潜在并发症？"
  },
  "options": {
    "A": {
      "en": "Autoimmune endocrinopathy",
      "zh": "自身免疫性内分泌病"
    },
    "B": {
      "en": "Graft versus host disease",
      "zh": "移植物抗宿主病"
    },
    "C": {
      "en": "Hypogammaglobulinemia",
      "zh": "低丙种球蛋白血症"
    },
    "D": {
      "en": "Myelofibrosis",
      "zh": "骨髓纤维化"
    },
    "E": {
      "en": "Prolonged myelosuppression",
      "zh": "长期骨髓抑制"
    }
  },
  "correct_answer": "C",
  "explanation": {
    "en": "Lymphocyte surface molecules are categorized using cluster of differentiation (CD) nomenclature to assist with immunophenotyping, the differentiation of immune cells based on cell surface features (ie, with flow cytometry). Although some CD molecules are expressed on most immune cells (eg, CD45), others are restricted to a specific population of leukocytes.\n\nCD19 is a transmembrane protein unique to B lymphocytes that reduces the cytokine threshold for B-cell activation and proliferation following antigen binding. Because B-cell cancers (eg. acute lymphocytic leukemia, diffuse B-cell lymphoma) often overexpress CD19 to increase replication rate, anti-CD19 immunotherapy has been developed to treat these malignancies.\n\nCAR T-cell therapy is a specific type of immunotherapy that involves the following:\n\n1. Extraction and purification of T cells from a patient or donor\n\n2. Genetic modification to form a chimeric antigen receptor (CAR), which combines an extracellular antigen recognition domain for an antigen overexpressed in a tumor with an intracellular stimulatory T-cell signaling domain that promotes T-cell activation/proliferation and tumor-killing activity.\n\n3. Reinfusion of the modified T cells into the patient\n\nBinding the modified T-cell to its tumor antigen stimulates the release of inflammatory cytokines and promotes destruction of the cancer cell. The most serious adverse effect is a life-threatening cytokine storm, which must be countered with urgent anti–IL-6 treatment (eg, tocilizumab) to prevent death. In addition, anti-CD19 therapy in particular can also cause hypogammaglobulinemia due to destruction of healthy B cells/plasma cells. {{exhibit_1}}\n\n(Choice A) Autoimmune endocrinopathy sometimes occurs with immune checkpoint inhibitor therapy, which targets surface molecules (eg, PD-1, CTLA-4) on cytotoxic T cells. CD19 is only expressed on B-cells, not T-cells.\n\n(Choice B) Graft versus host disease occurs when allogeneic (non-self) immune cells attack host tissue. It does not occur with autologous immune cells because these cells are drawn from the patient and adequately differentiate self from non-self.\n\n(Choice D) Myelofibrosis, a chronic myeloproliferative disorder, is associated with exposure to ionizing radiation and toxic chemicals. However, CAR-T cell therapy is not associated with myelofibrosis. In addition, risk of secondary malignancy after CAR-T cell therapy appears to be low overall.\n\n(Choice E) Chemotherapy often causes transient myelosuppression due to destruction of rapidly dividing hematopoietic cells. Anti-CD19 therapy may reduce B-cell populations but does not significantly affect other hematologic cells.",
    "zh": "淋巴细胞表面分子使用分化簇 (CD) 命名法进行分类，以辅助免疫表型分析，即基于细胞表面特征（例如，通过流式细胞术）的免疫细胞分化。虽然一些CD分子在大多数免疫细胞（例如，CD45）上表达，但其他分子仅限于特定的白细胞群体。\n\nCD19是一种B淋巴细胞特有的跨膜蛋白，它降低了抗原结合后B细胞活化和增殖的细胞因子阈值。由于B细胞癌（例如，急性淋巴细胞白血病、弥漫性大B细胞淋巴瘤）经常过表达CD19以增加复制率，因此已经开发出抗CD19免疫疗法来治疗这些恶性肿瘤。\n\nCAR T细胞疗法是一种特殊的免疫疗法，涉及以下内容：\n\n1. 从患者或供体提取和纯化T细胞\n\n2. 基因修饰以形成嵌合抗原受体 (CAR)，它将肿瘤中过表达的抗原的细胞外抗原识别结构域与促进T细胞活化/增殖和杀伤肿瘤活性的细胞内刺激性T细胞信号传导结构域相结合。\n\n3. 将修饰后的T细胞回输到患者体内\n\n修饰的T细胞与其肿瘤抗原的结合刺激炎症细胞因子的释放并促进癌细胞的破坏。最严重的不良反应是危及生命的细胞因子风暴，必须通过紧急抗IL-6治疗（例如，托珠单抗）来对抗，以防止死亡。此外，特别是抗CD19疗法也可能由于破坏健康的B细胞/浆细胞而导致低丙种球蛋白血症。{{exhibit_1}}\n\n(选项A) 自身免疫性内分泌病有时会与免疫检查点抑制剂疗法一起发生，该疗法靶向细胞毒性T细胞上的表面分子（例如，PD-1、CTLA-4）。CD19仅在B细胞上表达，而不是T细胞。\n\n(选项B) 移植物抗宿主病发生在异体（非自体）免疫细胞攻击宿主组织时。它不会发生在自体免疫细胞中，因为这些细胞是从患者身上提取的，并且能够充分区分自体和非自体。\n\n(选项D) 骨髓纤维化是一种慢性骨髓增生性疾病，与接触电离辐射和有毒化学物质有关。然而，CAR-T细胞疗法与骨髓纤维化无关。此外，CAR-T细胞疗法后继发恶性肿瘤的风险总体上似乎较低。\n\n(选项E) 化疗通常由于破坏快速分裂的造血细胞而导致短暂的骨髓抑制。抗CD19疗法可能减少B细胞群体，但不会显着影响其他血液细胞。"
  },
  "summary": {
    "en": "This question tests knowledge of CAR T-cell therapy and its potential complications, specifically focusing on the mechanism of action and the resulting adverse effects. It requires understanding of the target antigen (CD19) and the cells expressing it (B lymphocytes). \n\nThe best approach is to understand the mechanism of CAR T-cell therapy, particularly its specificity for CD19 on B cells. Knowing that CD19 is specific to B cells and that the therapy targets and destroys these cells helps to identify hypogammaglobulinemia as a likely complication.",
    "zh": "本题考察了CAR T细胞疗法的知识及其潜在并发症，特别关注作用机制和由此产生的不良反应。它需要了解靶抗原（CD19）以及表达它的细胞（B淋巴细胞）。\n\n最好的方法是了解CAR T细胞疗法的机制，特别是其对B细胞上CD19的特异性。知道CD19对B细胞具有特异性，并且该疗法靶向并破坏这些细胞有助于确定低丙种球蛋白血症是可能的并发症。"
  },
  "tags": "CAR T-cell therapy; Immunotherapy; CD19; B lymphocytes; Hypogammaglobulinemia; Cytokine storm; Oncology; Hematology; Adverse effects; {{exhibit_2}}",
  "category": "Blood",
  "question_id": "15048",
  "has_exhibits": true,
  "exhibit_count": 2,
  "exhibit_files": [
    "image1.jpg",
    "image2.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Blood 23\\15048",
  "extracted_at": "2025-11-05T11:24:18.753899",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T16:27:30.932736",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}